Infliximab induces clonal expansion of γδ-T cells in Crohn's disease: A predictor of lymphoma risk?

PLoS ONE

Volumn 6, Issue 3, 2011, Pages

  Kelsen, Jens ^a   Dige, Anders ^a   Schwindt, Heinrich ^b   D'Amore, Francesco ^a   Pedersen, Finn S ^b   Agnholt, Jørgen ^a   Christensen, Lisbet A ^a   Dahlerup, Jens F ^a   Hvas, Christian L ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; ANTIINFLAMMATORY AGENT; LYMPHOCYTE ANTIGEN RECEPTOR; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; CELL CLONE; CELL EXPANSION; CELL POPULATION; CLINICAL ARTICLE; CLONAL VARIATION; CONTROLLED STUDY; CROHN DISEASE; DISEASE PREDISPOSITION; DOSE RESPONSE; FEMALE; FLOW CYTOMETRY; GAMMA DELTA T LYMPHOCYTE; HUMAN; HUMAN CELL; IMMUNOMODULATION; LYMPHOCYTE PROLIFERATION; MALE; PREDICTION; RISK FACTOR; SIDE EFFECT; T CELL LYMPHOMA; IMMUNOLOGY; LYMPHOMA; METABOLISM; MIDDLE AGED; POLYMERASE CHAIN REACTION; T LYMPHOCYTE;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; CROHN DISEASE; FEMALE; FLOW CYTOMETRY; HUMANS; LYMPHOMA; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; T-LYMPHOCYTES; YOUNG ADULT;

EID: 79953329803     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0017890     Document Type: Article

References (28)

1. Beetz S, Wesch D, Marischen L, Welte S, Oberg HH, et al. (2008) Innate immune functions of human gammadelta T cells. Immunobiology 213: 173-182.
2. Soderstrom K, Bucht A, Halapi E, Gronberg A, Magnusson I, et al. (1996) Increased frequency of abnormal gamma delta T cells in blood of patients with inflammatory bowel diseases. J Immunol 156: 2331-2339.
3. Giacomelli R, Parzanese I, Frieri G, Passacantando A, Pizzuto F, et al. (1994) Increase of circulating gamma/delta T lymphocytes in the peripheral blood of patients affected by active inflammatory bowel disease. Clin Exp Immunol 98: 83-88.
4. Miyazaki K, Yamaguchi M, Imai H, Kobayashi T, Tamaru S, et al. (2009) Gene expression profiling of peripheral T-cell lymphoma including gammadelta T-cell lymphoma. Blood 113: 1071-1074.
5. Mackey AC, Green L, Liang LC, Dinndorf P, Avigan M, (2007) Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 44: 265-267.
6. Belhadj K, Reyes F, Farcet JP, Tilly H, Bastard C, et al. (2003) Hepatosplenic gammadelta T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients. Blood 102: 4261-4269.
7. Thayu M, Markowitz JE, Mamula P, Russo PA, Muinos WI, et al. (2005) Hepatosplenic T-cell lymphoma in an adolescent patient after immunomodulator and biologic therapy for Crohn disease. J Pediatr Gastroenterol Nutr 40: 220-222.
8. Mackey AC, Green L, Leptak C, Avigan M, (2009) Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease: update. J Pediatr Gastroenterol Nutr 48: 386-388.
9. Ochenrider MG, Patterson DJ, Aboulafia DM, (2010) Hepatosplenic T-cell lymphoma in a young man with Crohn's disease: case report and literature review. Clin Lymphoma Myeloma Leuk 10: 144-148.
10. Moran G, Dillon J, Green J, (2009) Crohn's disease, hepatosplenic T-cell lymphoma and no biological therapy: are we barking up the wrong tree? Inflamm Bowel Dis 15: 1281-1282.
11. Navarro JT, Ribera JM, Mate JL, Granada I, Junca J, et al. (2003) Hepatosplenic T-gammadelta lymphoma in a patient with Crohn's disease treated with azathioprine. Leuk Lymphoma 44: 531-533.
12. Beaugerie L, Brousse N, Bouvier AM, Colombel JF, Lemann M, et al. (2009) Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 374: 1617-1625.
13. Rosh JR, Gross T, Mamula P, Griffiths A, Hyams J, (2007) Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: a cautionary tale? Inflamm Bowel Dis 13: 1024-1030.
14. D'Haens G, Rutgeerts P, (2009) Immunosuppression-associated lymphoma in IBD. Lancet 374: 1572-1573.
15. Shale M, Kanfer E, Panaccione R, Ghosh S, (2008) Hepatosplenic T cell lymphoma in inflammatory bowel disease. Gut 57: 1639-1641.
16. Sokol H, Beaugerie L, (2009) Inflammatory bowel disease and lymphoproliferative disorders: the dust is starting to settle. Gut 58: 1427-1436.
17. Stange EF, Travis SP, Vermeire S, Beglinger C, Kupcinkas L, et al. (2006) European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. Gut 55 (Suppl 1): i1-15.
18. Harvey RF, Bradshaw JM, (1980) A simple index of Crohn's-disease activity. Lancet 1: 514.
19. Sipponen T, Savilahti E, Karkkainen P, Kolho KL, Nuutinen H, et al. (2008) Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn's disease. Inflamm Bowel Dis 14: 1392-1398.
20. Dige A, Hvas CL, Kelsen J, Deleuran B, Dahlerup JF, et al. (2010) Ethylene-Diamine-Tetra-Acetate (EDTA) mimics the effect of regulatory T cells in suppression assays: a potential pitfall when using AutoMACS-separated cells. J Immunol Methods 353: 141-144.
21. van Dongen JJ, Langerak AW, Bruggemann M, Evans PA, Hummel M, et al. (2003) Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 17: 2257-2317.
22. Prefontaine E, Sutherland LR, Macdonald JK, Cepoiu M, (2009) Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev CD000067.
23. Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, et al. (2010) Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 362: 1383-1395.
24. Holtmeier W, Hennemann A, May E, Duchmann R, Caspary WF, (2002) T cell receptor delta repertoire in inflamed and noninflamed colon of patients with IBD analyzed by CDR3 spectratyping. Am J Physiol Gastrointest Liver Physiol 282: G1024-G1034.
25. Hvas CL, Kelsen J, Agnholt J, Dige A, Christensen LA, et al. (2010) Discrete changes in circulating regulatory T cells during infliximab treatment of Crohn's disease. Autoimmunity 43: 325-333.
26. Atreya I, Neurath MF, (2009) Understanding the delayed onset of action of azathioprine in IBD: are we there yet? Gut 58: 325-326.
27. Iqbal J, Liu Z, Deffenbacher K, Chan WC, (2009) Gene expression profiling in lymphoma diagnosis and management. Best Pract Res Clin Haematol 22: 191-210.
28. Iqbal J, Weisenburger DD, Greiner TC, Vose JM, McKeithan T, et al. (2010) Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma. Blood 115: 1026-1036.